Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Orphan Drug

PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944397

Cover Image

PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1944397

Sarcoidosis Drug Market, By Mechanism of Action, By Route of Administration, By Drug, By Type, By End-Use, By Age Group, By Indication, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

PUBLISHED:
PAGES: 329 Pages
DELIVERY TIME: 2-3 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 3250
PDF (5 User License)
USD 4650
PDF & Excel (Enterprise User License)
USD 5650

Add to Cart

Description

Table of Contents

Sarcoidosis Drug Market size was valued at US$ 7,201.10 Million in 2024, expanding at a CAGR of 6.12% from 2025 to 2032.

The Sarcoidosis Drug Market includes pharmaceutical therapies used to treat sarcoidosis, an inflammatory disease characterized by granuloma formation in organs such as the lungs, skin, and lymph nodes. The rising prevalence of autoimmune and inflammatory disorders, increased diagnosis rates, and improved clinical awareness are the primary drivers of market growth. To reduce side effects, the market is gradually shifting away from long-term corticosteroid use and toward immunosuppressants and biologic therapies. However, there are few disease-specific drugs that have been approved, and disease heterogeneity is still a major barrier. Despite this, opportunities are emerging through ongoing clinical research, orphan drug development, and targeted biologics to improve long-term patient outcomes and treatment precision.

Sarcoidosis Drug Market- Market Dynamics

Increased emphasis on research and development

The sarcoidosis drug market is increasingly shaped by intensive research and development efforts aimed at advancing novel therapies and enhancing patient outcomes. This focus has encouraged the adoption of targeted treatments and personalized medicine approaches to better manage the disease's clinical complexity. At present, treatment largely depends on the off-label use of corticosteroids and immunosuppressants, which are often associated with safety concerns and variable therapeutic effectiveness. Consequently, the development of alternative treatment options remains a critical priority.

For instance, in February 2025, Roivant Sciences announced plans to initiate a Phase II clinical trial of brepocitinib, an oral dual TYK2 and JAK1 inhibitor, for the treatment of adults with cutaneous sarcoidosis. The study is scheduled to commence in April 2026, with results anticipated in the latter half of 2026.

Sarcoidosis Drug Market- Segmentation Analysis:

The Global Sarcoidosis Drug Market is segmented on the basis of Mechanism of Action, Route of Administration, Drug, Type, End-Use, Age Group, Indication, and Region.

The pulmonary sarcoidosis segment accounts for a significant share of the sarcoidosis drug market because it is distinguished by the presence of granulomas in the lungs and is the most common type of sarcoidosis, affecting 90% of people. The high prevalence highlights the need for targeted treatments and investigations into pulmonary symptoms. Market dominance is associated with higher prevalence rates, ongoing research into innovative therapies, and increased awareness among healthcare providers and patients. Serious conditions like pulmonary hypertension and permanent lung fibrosis highlight the need for targeted treatments. In November 2022, Kinevant Sciences initiated the RESOLVE-Lung study to evaluate namilumab, a monoclonal antibody that targets GM-CSF, for the treatment of pulmonary sarcoidosis. The study, which included 107 participants, is expected to produce preliminary findings by the end of 2024.

Based on the Drug: Prednisone dominate the sarcoidosis drug market in 2025 because it is widely recognized as the primary treatment for sarcoidosis. As a corticosteroid, it reduces immune response, inflammation, and symptoms, particularly in respiratory cases. Clinical guidelines consistently recommend prednisone as the standard therapy, emphasizing its importance as a foundational treatment. Its widespread acceptance, affordability, and clinical familiarity make it a popular choice among healthcare professionals for prolonged treatment. Prednisone's effectiveness in inflammation management, combined with its widespread use, contributed to its market prevalence. According to the 2020 study, 59.3% of sarcoidosis patients are treated with corticosteroids, while 24.7% receive long-term treatment. The prolonged use, combined with significant side effects, emphasizes the need for safer and more effective treatment options.

Sarcoidosis Drug Market- Geographical Insights

North America holds significant share in the sarcoidosis drug market due to its high prevalence, especially with cardiac involvement, robust healthcare infrastructure, active research and development programs, and partnerships between pharmaceutical companies, academic entities, healthcare professionals, and patient advocacy organizations. The region's well-established healthcare infrastructure allows early detection and thorough management of sarcoidosis, providing patients with specialized treatment and the latest medicines. Sarcoidosis therapy advances with major pharmaceutical companies and research organizations, which collaborate to share knowledge and accelerate disease management.

In April 2024, the Foundation for Sarcoidosis Research partnered with Walgreens to raise sarcoidosis awareness and promote spring vaccinations in Alabama, emphasizing community impact and encouraging donations to research and patient assistance initiatives.

United States Sarcoidosis Drug Market- Country Insights

The U.S. sarcoidosis drug market accounted for a sizable revenue share in North America in 2024, owing to the disease's high prevalence, particularly among African Americans, who frequently suffer from more severe forms of the disease. This is complemented by a well-developed healthcare system, extensive research and development activities, and a strong presence of major pharmaceutical corporations. Patients in the United States have access to advanced diagnostics and a wide range of therapies, including novel biologics and orphan drugs. Strong funding for sarcoidosis research, as well as strategic collaborations between academic institutions and industry players, are driving market growth and establishing the United States as a leader in sarcoidosis drug development and adoption.

Sarcoidosis Drug Market- Competitive Landscape:

The sarcoidosis drug market is moderately competitive, with established pharmaceutical companies and emerging players offering anti-inflammatory, immunosuppressive, and biologic therapies. Market participants compete primarily based on product efficacy, safety profiles, and expanded indications. Corticosteroids remain the primary first-line treatment, but immunosuppressants and biologics are gaining popularity for chronic and refractory cases. Companies are also investing in clinical trials and pipeline expansion to meet unmet medical needs, particularly for steroid-free treatments. Strategic collaborations, research partnerships, and regulatory approvals all play an important role in maintaining market positions. Key players in the sarcoidosis drug market include Novartis AG, Kinevant Sciences GmbH, Molecure S.A, aTyr Pharma, all of which rely on strong R&D capabilities and global distribution networks to stay competitive.

In November 2024, The Foundation for Sarcoidosis Research awarded Dr. Eliot Peyster and Dr. Ravi Karra USD 100,000 to advance the diagnosis and treatment of cardiac sarcoidosis, with a focus on establishing new diagnostic benchmarks and reusing imaging agents.

Recent Developments:

In April 2024, aTyr Pharma has launched a global Phase III EFZO-FIT(TM) trial to assess efzofitimod, an innovative treatment aimed at neuropilin-2 for pulmonary sarcoidosis that has been granted orphan drug designations in the U.S., EU, and Japan.

In March 2025, Xentria, Inc. reported significant progress in its XTMAB-16 study for pulmonary sarcoidosis, including the successful enrollment of patients in the dose-ranging study. XTMAB-16 is a new anti-TNF-a monoclonal antibody being developed as a potential treatment for pulmonary sarcoidosis. This advancement demonstrates Xentria's commitment to addressing the unmet need for targeted therapies in sarcoidosis, with the next phase of research, which will include additional patient screening, set to begin in Fall 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SARCOIDOSIS DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Pfizer Inc
  • Amgen Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Kinevant Sciences GmbH
  • Molecure S.A
  • aTyr Pharma
  • Merck & Co., Inc
  • Xentria
  • United Therapeutics Corporation
  • Relief Therapeutics
  • Mallinckrodt
  • AbbVie Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • GSK plc.
  • Theravance Biopharma
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antimalarial
  • Immunosuppressants
  • Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
  • Corticosteroid

GLOBAL SARCOIDOSIS DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Injectable
  • Oral
  • Topical

GLOBAL SARCOIDOSIS DRUG MARKET, BY DRUG- MARKET ANALYSIS, 2019 - 2032

  • Hydroxychloroquine
  • Azathioprine
  • Corticotropin
  • Dexamethasone
  • Colchicine
  • Chloroquine
  • Prednisone
  • Methotrexate
  • Deltasone

GLOBAL SARCOIDOSIS DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hepatic Sarcoidosis
  • Renal Sarcoidosis
  • Sarcoidosis of the Spleen and Bone Marrow
  • Pulmonary Sarcoidosis
  • Musculoskeletal Sarcoidosis
  • Cutaneous Sarcoidosis
  • Ocular Sarcoidosis
  • Cardiac Sarcoidosis
  • Neurosarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Surgical Centers
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatric
  • Adult
  • Geriatric

GLOBAL SARCOIDOSIS DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Extrapulmonary Sarcoidosis
  • Pulmonary Sarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA
Show more
Product Code: ANV6020

Table of Contents

1. Sarcoidosis Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sarcoidosis Drug Market Snippet by Mechanism of Action
    • 2.1.2. Sarcoidosis Drug Market Snippet by Route of Administration
    • 2.1.3. Sarcoidosis Drug Market Snippet by Drug
    • 2.1.4. Sarcoidosis Drug Market Snippet by Type
    • 2.1.5. Sarcoidosis Drug Market Snippet by End-Use
    • 2.1.6. Sarcoidosis Drug Market Snippet by Age Group
    • 2.1.7. Sarcoidosis Drug Market Snippet by Indication
    • 2.1.8. Sarcoidosis Drug Market Snippet by Country
    • 2.1.9. Sarcoidosis Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Sarcoidosis Drug Key Market Trends

  • 3.1. Sarcoidosis Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sarcoidosis Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sarcoidosis Drug Market Opportunities
  • 3.4. Sarcoidosis Drug Market Future Trends

4. Sarcoidosis Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sarcoidosis Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Sarcoidosis Drug Market Landscape

  • 6.1. Sarcoidosis Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sarcoidosis Drug Market - By Mechanism of Action

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 7.1.2. Antimalarial
    • 7.1.3. Immunosuppressants
    • 7.1.4. Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
    • 7.1.5. Corticosteroid

8. Sarcoidosis Drug Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Injectable
    • 8.1.3. Oral
    • 8.1.4. Topical

9. Sarcoidosis Drug Market - By Drug

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug, 2024 & 2032 (%)
    • 9.1.2. Hydroxychloroquine
    • 9.1.3. Azathioprine
    • 9.1.4. Corticotropin
    • 9.1.5. Dexamethasone
    • 9.1.6. Colchicine
    • 9.1.7. Chloroquine
    • 9.1.8. Prednisone
    • 9.1.9. Methotrexate
    • 9.1.10. Deltasone

10. Sarcoidosis Drug Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 10.1.2. Hepatic Sarcoidosis
    • 10.1.3. Renal Sarcoidosis
    • 10.1.4. Sarcoidosis of the Spleen and Bone Marrow
    • 10.1.5. Pulmonary Sarcoidosis
    • 10.1.6. Musculoskeletal Sarcoidosis
    • 10.1.7. Cutaneous Sarcoidosis
    • 10.1.8. Ocular Sarcoidosis
    • 10.1.9. Cardiac Sarcoidosis
    • 10.1.10. Neurosarcoidosis

11. Sarcoidosis Drug Market - By End-Use

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Use, 2024 & 2032 (%)
    • 11.1.2. Surgical Centers
    • 11.1.3. Hospitals & Clinics
    • 11.1.4. Diagnostic Centers
    • 11.1.5. Others

12. Sarcoidosis Drug Market - By Age Group

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 12.1.2. Pediatric
    • 12.1.3. Adult
    • 12.1.4. Geriatric

13. Sarcoidosis Drug Market - By Indication

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 13.1.2. Extrapulmonary Sarcoidosis
    • 13.1.3. Pulmonary Sarcoidosis

14. Sarcoidosis Drug Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Sarcoidosis Drug Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Sarcoidosis Drug Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Sarcoidosis Drug Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Sarcoidosis Drug Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Sarcoidosis Drug Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Sarcoidosis Drug Industry

  • 15.1. Competitive Benchmarking
    • 15.1.1. Competitive Dashboard
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Janssen Pharmaceutical Companies of Johnson & Johnson
    • 15.2.2. Pfizer Inc
    • 15.2.3. Amgen Inc.
    • 15.2.4. Bristol Myers Squibb
    • 15.2.5. Novartis AG
    • 15.2.6. Kinevant Sciences GmbH
    • 15.2.7. Molecure S.A
    • 15.2.8. aTyr Pharma
    • 15.2.9. Merck & Co., Inc
    • 15.2.10. Xentria
    • 15.2.11. United Therapeutics Corporation
    • 15.2.12. Relief Therapeutics
    • 15.2.13. Mallinckrodt
    • 15.2.14. AbbVie Inc.
    • 15.2.15. Kyorin Pharmaceutical Co., Ltd.
    • 15.2.16. Boehringer Ingelheim International GmbH
    • 15.2.17. Sanofi
    • 15.2.18. GSK plc.
    • 15.2.19. Theravance Biopharma
    • 15.2.20. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!